


MAY 21 2002

JC14 Rec'd PCT/PTO 21 MAY 2002

PCT  
#3

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 8, 2002.

  
Brian Bixby  
Attorney for Applicants

PATENT APPLICATION  
Docket No. 1321.2.34.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David A. Jones et al. )  
                                          )  
Serial No.: 10/089,862              )  
                                          )  
Filing Date: April 2, 2002         )  
                                          )  
For: TRDL-1 GAMMA, A NOVEL TUMOR NECROSIS- )  
      LIKE LIGAND                      )

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

Sir:

This Information Disclosure Statement discloses information which has come to the attention of applicants and/or their attorneys and is being submitted so as to comply with the duty of disclosure set forth in 37 C.F.R. § 1.56. In accordance with 37 C.F.R. § 1.97(b), this Statement is being filed within three (3) months of the filing date of the above-identified application or before the mailing date of a first Action on the merits.

Neither applicants nor their attorneys make any representation that any information disclosed herein may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103. Moreover, pursuant to 37 C.F.R. § 1.97, the filing of this Information Disclosure Statement

shall not be construed as a representation that a search has been made or as an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.98, this Information Disclosure Statement includes and is accompanied by:

1. A completed copy of Form PTO-1449 listing the patents, publications and other information being submitted for consideration; and
2. A legible copy of each patent, publication and other item of information in written form listed on the enclosed Form PTO-1449.

Respectfully submitted,



Eric M. Barzee  
Reg. No. 45,911  
Attorney for Applicants

Date: May 8, 2002

MADSON & METCALF  
Gateway Tower West  
15 West South Temple, Suite 900  
Salt Lake City, Utah 84101  
Telephone: 801/537-1700



FORM PTO-1449  <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (use several sheets if necessary)	SERIAL NO. 10/089,862	ATTORNEY DOCKET NO. 1321.2.34.1
	FILING DATE April 2, 2002	GROUP ART UNIT
	APPLICANT(S): David A. Jones et al.	

**REFERENCE DESIGNATION****NON-PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT (Including Author, Title, Source, and Pertinent Pages)
	A1	Hahne, Michael, et al., "APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," J. Exp. Med. Vol. 188, No. 6, 09/21/1998, 1185-90

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).